An additional recent example in the pediatric field includes the evaluation of plasma copeptin, urinary epidermal growth factor (EGF) and urinary MCP-1 as potential early markers in a cross-sectional study of 53 genotyped ADPKD patients with a mean age of 10.4 years. This evidence concerns the gene CCL2 and autosomal dominant polycystic kidney disease.